Key Statistics
About Harrow Health, Inc. 11.875% Senior Notes due 2027
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Analyst Ratings
View All →| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2025 | Ladenburg Thalmann | |
| Nov 12, 2025 | HC Wainwright & Co. | |
| Oct 1, 2025 | B. Riley Securities | |
| Sep 29, 2025 | Lake Street | |
| Sep 29, 2025 | HC Wainwright & Co. |